Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics

Purpose: Psoriasis is a chronic, immune-mediated inflammatory skin condition marked by erythematous, scaly plaques. This retrospective observational study evaluated the long-term efficacy and safety of bimekizumab, a dual IL-17A and IL-17F inhibitor, in treating moderate to severe plaque psoriasis i...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	E. Mortato, F. Artosi, C. Borselli, I. Compagnucci, Antonia Rivieccio, C. Lanna, S. Lambiase, R. Gaeta Shumak, F. Loconsole, L. Bianchi, E. Campione
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Taylor & Francis Group 2025-12-01
Reeks:	Journal of Dermatological Treatment
Onderwerpen:	Psoriasis PASI interleukin 17 bimekizumab DLQI
Online toegang:	https://www.tandfonline.com/doi/10.1080/09546634.2024.2432932
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!